Melanoma Research Victoria

Source:  Evaluate, November 2018 Oncology projects that disrupt the tumour microenvironment are hot property, and – after Aduro’s $225m deal with Novartis and Bristol-Myers Squibb’s $300m takeover of IFM Therapeutics – the Sting pathway is seen as particularly attractive. This is why the first clinical data with Merck & Co’s Sting agonist MK-1454, presented at […]

Read the full story

Source: Ecancer, November 2018 Prof Paolo Ascierto speaks with ecancer at ESMO 2018 in Munich about results from a phase 2 randomised study of dabrafenib and trametinib plus PD-L1 checkpoint therapy pembrolizumab for BRAFm advanced melanoma. Prof Ascierto discusses how immuno-oncology is adding to melanoma treatment, with the dabrafenib trametinib combination already found effective in the adjuvant […]

Read the full story

Source: OnLive, November 2018 Long-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival (RFS) advantage for patients with resected stage III BRAF-mutant melanoma treated with adjuvant dabrafenib (Tafinlar) plus trametinib (Mekinist). Patients randomized to adjuvant dabrafenib plus trametinib had a 4-year relapse-free survival (RFS) rate of 54%, as compared with 38% for […]

Read the full story

Source: News Medical Life Sciences, November 2018 Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial – the longest follow-up to date – which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma. With a minimum follow-up of 48 […]

Read the full story